Skip to main content

Advertisement

SpringerLink
Log in

Perspective of trastuzumab treatment

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Trastuzumab (Herceptin©) has many benefits for metastatic breast cancer patients with HER2 overex-pression/amplification. Trastuzumab alone or trastuzumab in combination with chemotherapy regimens are standard treatment worldwide as first line therapy for metastatic breast cancer patients with HER2 overexpression/amplification. Furthermore, an international collaboration for adjuvant trastuzumab trials showed last year that trastuzumab treatment improves disease-free and overall survival after or in combination with adjuvant chemotherapy. However, there are many uncertain issues concerning trastuzumab adjuvant and metastatic treatment, such as treatment beyond disease progression (PD), combination with hormone therapy, duration of adjuvant treatment, and cardiac safety of long term treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

DFS:

disease-free survival

OS:

overall survival

PD:

progressive disease

NSABP:

National Surgical Adjuvant Breast and Bowel Project

NCCTG:

North Central Cancer Treatment Group

BCIRG:

Breast Cancer International Research Group

NCCN:

National Comprehensive Cancer Network

ITT:

Intent-to-treat

IDMC:

Independent Data Monitoring Committee

pCR:

pathological complete response

ER:

estrogen receptor

PgR:

progesterone receptor

ESMO:

European Society of Medical Oncology

Al:

aromatase inhibitors

TTP:

Time to progression

LVEF:

left ventricular ejection fraction

References

  1. Yarden Y, Sliwkowski M: (Untangling the ErbB signaling network).Nat rev Mol Cell Bio 2:127–137, 2001.

    Article  CAS  Google Scholar 

  2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: (Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu proto-oncogene in human breast and ovarian cancer).Science 244:707–712, 1989.

    Article  CAS  Google Scholar 

  3. Vogel CL, Cobleigh MATripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: (Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer).J Clin Oncol 20:719–726, 2002.

    Article  CAS  Google Scholar 

  4. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P: (Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab monotherapy administered on a 3-weekly schedule).J Clin Oncol 23:2162–2171, 2005.

    Article  CAS  Google Scholar 

  5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD: (Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer).N Engl J Med 353:1659–1672, 2005.

    Article  CAS  Google Scholar 

  6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: (Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer).N Engl J Med 353:1673–1684, 2005.

    Article  CAS  Google Scholar 

  7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baslega J, Norton L: (Concurrent administration of anti-HER2 monoclonal antibody and firstline chemotherapy for HER2overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial).N Engl J Med 344:783–792, 2001.

    Article  CAS  Google Scholar 

  8. Hortogagyi GN: (Treatment of Breast Cancer).N Engl J Med 339:974–984, 1998.

    Article  Google Scholar 

  9. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O’Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: (Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 study group).J Clin Oncol 23:4265–4274, 2005.

    Article  CAS  Google Scholar 

  10. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP: (Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markerd as predictive factors, and cardiac surveillance algorithm).J Clin Oncol 21:2889–2895, 2003.

    Article  CAS  Google Scholar 

  11. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Von Minckwitz G, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J: Phase III Trial Comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in the Adjuvant Treatment of HER2 positive Early Breast Cancer Patients: First Interim Efficacy Analysis.Breast Cancer Res Treat 94:s5(abstr 1) 2005.

    Google Scholar 

  12. Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J: (Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer).N Engl J Med 354:809–820, 2006.

    Article  CAS  Google Scholar 

  13. Smith IE, and The HERA Study Team: Trastuzumab Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer (HERA Trial): Disease-Free and Overall Survival after 2 Year Median Follow-Up. J Clin Oncol 24: Scientific Symposium, 2006

  14. NCCN Clinical Practice Guidelines in Oncology version 2. 2006. Breast Cancer http://www.nccn.org

  15. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn HJ: First—select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol: Epub ahead of print, 2006.

    Article  CAS  Google Scholar 

  16. Sachelarie I, Grossbard ML,, Chadha M, Feldman S, Ghesani M, Blum RH: (Primary Systemic Therapy of Breast Cancer).The Oncologist 11:574–589, 2006.

    Article  CAS  Google Scholar 

  17. Nakamura S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Shin E, Yamazaki K, Hisamatsu K, Sato Y, Kaise H, Kashiwaba M, Kurosumi M, Tsuda H, Akiyama F: The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC100) followed by docetaxel (DOC75) in primary operable breast cancer.Eur J Cancer 4:156(abstr 370), 2006.

    Article  Google Scholar 

  18. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: (Significantly higher pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2 positive operable breast cancer).J Clin Oncol 23:3676–3685, 2005.

    Article  CAS  Google Scholar 

  19. Kaufman, B: (On behalf of the TAnDEM investigators. Trastuzumab + anastrozole in postmenopausal women with HER2-positive, HR-positive MBC: results of the TAnDEM study).Ann Oncol 17: LBA2, 2006.

    Article  Google Scholar 

  20. Geyer CE, Cameron D, Lindquist D, Chan S, Pienkowski T, Romieu CG, Jagiello-Gruszfield A, Crown J, Kaufman B, Chan A, Forster JK: A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Clin Oncol 24: late breaking session, 2006.

  21. Iwata H, Toi M, Fujiwara Y, Ito Y, Fujii H, Nakamura S, Aogi K, Zaks T, Sasaki Y, Takashima S: Phase II Clinical Study of Lapatinib (GW572016) in Patients with Advanced or Metastatic Breast Cancer. Breast Cancer Res Treat: abstr 1091, 2006.

  22. Geyer CE Jr, Brtant JL, Romond EH, Ewer MS, Keefe DL, Shannon RP, Levine TB, Rastogi P, Swain SM, Wolmark N: (Four Year Update of Cardiac Dysfunction on NSABP B-31: A Randomized Trial of AC->Paclitaxel vs. AC->Paclitaxel with Trastuzumab in HER2 Positive, Node Positive Operable Breast Cancer).J Clin Oncol 24:23s (abstr 581), 2006.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Oncology, Aichi Cancer Center Hospital, Japan

    Hiroji Iwata

Authors
  1. Hiroji Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroji Iwata.

About this article

Cite this article

Iwata, H. Perspective of trastuzumab treatment. Breast Cancer 14, 150–155 (2007). https://doi.org/10.2325/jbcs.955

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2325/jbcs.955

Key words

Search

Navigation